Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study.
Beugeling M, Amssoms K, Cox F, De Clerck B, Van Gulck E, Verwoerd JA, Kraus G, Roymans D, Baert L, Frijlink HW, Hinrichs WLJ. Beugeling M, et al. Among authors: kraus g. Pharmaceutics. 2019 Oct 3;11(10):510. doi: 10.3390/pharmaceutics11100510. Pharmaceutics. 2019. PMID: 31623333 Free PMC article.
Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice.
Amssoms K, Born PA, Beugeling M, De Clerck B, Van Gulck E, Hinrichs WLJ, Frijlink HW, Grasmeijer N, Kraus G, Sutmuller R, Simmen K, Baert L. Amssoms K, et al. Among authors: kraus g. PLoS One. 2018 Aug 30;13(8):e0202961. doi: 10.1371/journal.pone.0202961. eCollection 2018. PLoS One. 2018. PMID: 30161264 Free PMC article.
Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Baert L, van 't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. Baert L, et al. Among authors: kraus g. Eur J Pharm Biopharm. 2009 Aug;72(3):502-8. doi: 10.1016/j.ejpb.2009.03.006. Epub 2009 Mar 27. Eur J Pharm Biopharm. 2009. PMID: 19328850
Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1.
Nischang M, Sutmuller R, Gers-Huber G, Audigé A, Li D, Rochat MA, Baenziger S, Hofer U, Schlaepfer E, Regenass S, Amssoms K, Stoops B, Van Cauwenberge A, Boden D, Kraus G, Speck RF. Nischang M, et al. Among authors: kraus g. PLoS One. 2012;7(6):e38853. doi: 10.1371/journal.pone.0038853. Epub 2012 Jun 13. PLoS One. 2012. PMID: 22719966 Free PMC article.
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT. Azijn H, et al. Among authors: kraus g. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23. Antimicrob Agents Chemother. 2010. PMID: 19933797 Free PMC article.
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. Dierynck I, et al. Among authors: kraus g. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896904 Free PMC article.
287 results